Melbourne, Feb 11, 2008 (ABN Newswire) - Biota Holdings Limited (ASX: BTA) today announced that its long acting neuraminidase inhibitor (LANI), CS8958, an antiviral influenza treatment, has completed enrolment for its Phase II clinical study in Japan. The Phase II trial commencement was advised in an ASX Release on 22 November 2007.
